[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Young Kwon Biography and Net Worth

Director of ADMA Biologics

Dr. Kwon is presently an operating partner at Lightstone Ventures (“LSV”), assisting the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio management. Prior to LSV, he served as Chief Financial and Business Officer at Momenta Pharmaceuticals, a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, where he most recently led the sale of Momenta to Johnson & Johnson for approximately $6.5 billion in 2020. At Momenta, he led all finance-related and business development initiatives, including those pertaining to the development efforts of M254, Momenta’s hypersialylated IG clinical program. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions.

Dr. Kwon received a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University and a B.S. in Biology from MIT.

What is Young Kwon's net worth?: The estimated net worth of Young Kwon is at least $5.11 million as of August 23rd, 2024. Dr. Kwon owns 241,441 shares of ADMA Biologics stock worth more than $5,113,720 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Kwon may own. Learn More about Young Kwon's net worth.
How do I contact Young Kwon?: The corporate mailing address for Dr. Kwon and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Young Kwon's contact information.
Has Young Kwon been buying or selling shares of ADMA Biologics?: Young Kwon has not been actively trading shares of ADMA Biologics during the last ninety days. Most recently, Young Kwon sold 60,000 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a transaction totalling $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company's stock, valued at $4,408,712.66. Learn More on Young Kwon's trading history.
Who are ADMA Biologics' active insiders?: ADMA Biologics' insider roster includes Steve Elms (Director), Bryant Fong (Director), Adam Grossman (Co-Founder, President, CEO & Director), Jerrold Grossman (Director), Lawrence Guiheen (Director), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.
Are insiders buying or selling shares of ADMA Biologics?: During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 1,221,795 shares worth more than $13,540,539.83. The most recent insider tranaction occured on November, 22nd when CFO Brad L Tade sold 15,000 shares worth more than $317,250.00. Insiders at ADMA Biologics own 3.7% of the company. Learn More about insider trades at ADMA Biologics.
Information on this page was last updated on 11/22/2024.

Young Kwon Insider Trading History at ADMA Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2024	Sell	60,000	$18.26	$1,095,600.00	241,441
8/24/2023	Buy	25,000	$3.90	$97,500.00	277,401
10/25/2021	Buy	100,000	$1.00	$100,000.00

Young Kwon Buying and Selling Activity at ADMA Biologics

ADMA Biologics Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Today's Range

Now: $21.18

$20.88

$21.48

50 Day Range

MA: $18.86

$15.62

$22.62

2 Week Range

Now: $21.18

$3.60

$23.64

Volume

2,107,830 shs

Average Volume

3,886,240 shs

Market Capitalization

$5.01 billion

P/E Ratio

75.64

Dividend Yield

N/A

Beta

0.64